# Sanofi (SNY) Q2 2026 earnings

Results filed 2026-07-30 for the quarter ended 2026-06-30. Source page: https://earnings.opennash.com/companies/sny/2026-q2/
Press release and documents: https://www.sec.gov/Archives/edgar/data/1121404/000162828026050803/0001628280-26-050803-index.htm
> Summaries and transcripts are machine-generated and can contain errors.

## In brief

Sanofi bought Dynavax for its two-dose adult hepatitis B vaccine while dropping amlitelimab and itepekimab, and a new CEO began reprioritizing the pipeline around Dupixent and newer launches.

Sanofi closed the Dynavax acquisition on February 10, 2026, adding HEPLISAV-B, a two-dose adult hepatitis B vaccine, and a shingles candidate. Dupixent gained approvals in allergic fungal rhinosinusitis and pediatric chronic spontaneous urticaria, while Ayvakit and ALTUVIIIO also drove growth. Tzield, Cenrifki and subcutaneous Sarclisa won new approvals, but several late-stage programs failed or were stopped.
Belén Garijo became CEO on May 1, 2026, after Paul Hudson was removed, and management has begun pipeline prioritization. The company is adding in-licensed assets such as rovadicitinib and KT501 while ending programs that did not clear the bar. The tension is that Dupixent remains the top seller and its primary US compound patent expires in March 2031, so replacements must mature in time.

## Key numbers

| Metric | Value | Change | Basis |
| --- | --- | --- | --- |
| Net sales (first half 2026) | €22,106 million | 11.1% higher than in the first half of 2025 | GAAP |
| Net income attributable to equity holders (first half 2026) | €1,957 million | versus €5,812 million in the first half of 2025 | GAAP |
| Diluted EPS (first half 2026, €) | 1.62 | versus 4.72 in the first half of 2025 | GAAP |
| Business EPS (first half 2026) | €3.97 | up 17.1% | non-GAAP |
| Gross profit as % of net sales (first half 2026) | 78.7% | versus 77.7% in the first half of 2025 | GAAP |
| Operating income (first half 2026) | €3,168 million | versus €3,759 million in the first half of 2025 | GAAP |
| Operating income as % of net sales (first half 2026) | 14.3% | versus 18.9% in the first half of 2025 | GAAP |
| Net cash from continuing operating activities (first half 2026, € million) | 4,643 | versus 3,367 in the first half of 2025 | GAAP |
| Business operating income (first half 2026) | €6,258 million | versus €5,363 million in the first half of 2025 | non-GAAP |

## Segments and operating metrics

| Name | Value | Change |
| --- | --- | --- |
| Net sales growth at constant exchange rates (first half 2026) | 15.7% |  |
| Dynavax net sales contribution since acquisition | €144 million |  |
| Net debt at June 30, 2026 (€ million) | 15,513 | versus 11,008 at December 31, 2025 |

## Key takeaways

1. **Dynavax deal adds adult vaccine and shingles candidate** Sanofi completed the acquisition on February 10, 2026, bringing HEPLISAV-B, marketed in the US with a two-dose, one-month schedule versus three doses over six months, plus shingles candidate Z-1018 in phase 1/2. It deepens Sanofi's adult immunization offering.
2. **Dupixent keeps widening its label** The FDA approved Dupixent for allergic fungal rhinosinusitis, and the FDA and European Commission approved it for children aged two to 11 with chronic spontaneous urticaria. Japan approved it for bullous pemphigoid, but Sanofi withdrew its EU application there and lichen simplex chronicus phase 3 studies missed their endpoints.
3. **Amlitelimab and itepekimab dropped from the pipeline** Sanofi will not file amlitelimab in atopic dermatitis because the evidence does not show a meaningful improvement over standard of care, and itepekimab was discontinued in COPD and chronic rhinosinusitis. Riliprubart's MOBILIZE phase 3 in CIDP was also stopped for likely insufficient efficacy.
4. **New CEO Belén Garijo starts pipeline prioritization** The Board removed Paul Hudson as CEO in February, Olivier Charmeil served as interim, and Belén Garijo took over on May 1, 2026. An Executive Committee reshuffle takes effect September 1, 2026, with a dedicated head of Research & Development.
5. **Licensing deals refill immunology and oncology pipeline** Sanofi licensed rovadicitinib, a JAK/ROCK inhibitor already approved in China for myelofibrosis, with an upfront payment of $135 million. It also licensed Kali Therapeutics' tri-specific T-cell engager KT501 for autoimmune disease.

## Questions

**What did Sanofi acquire this quarter and why?** Sanofi completed the Dynavax acquisition on February 10, 2026, gaining the marketed adult hepatitis B vaccine HEPLISAV-B and the shingles candidate Z-1018. It strengthens Sanofi's adult immunization presence.
**Which programs did Sanofi stop?** Sanofi will not file amlitelimab in atopic dermatitis, discontinued itepekimab in COPD and chronic rhinosinusitis, and halted the riliprubart MOBILIZE study in CIDP. Venglustat also missed its primary endpoint in two Fabry disease phase 3 studies.
**Who leads Sanofi now?** Belén Garijo became CEO on May 1, 2026, succeeding Paul Hudson, whom the Board relieved in February. Olivier Charmeil was interim CEO in between.
**What is the main long-term risk to Dupixent?** Dupixent is Sanofi's top-selling product, and its primary US compound patent expires in March 2031. Pipeline setbacks make replacing it harder.
**What new products or approvals moved forward?** Cenrifki won EU approval for non-relapsing secondary progressive MS, Tzield was approved for younger children and for recently diagnosed stage 3 type 1 diabetes, and subcutaneous Sarclisa was approved via an on-body injector. Venglustat has FDA priority review for type 3 Gaucher disease with a decision date of November 25, 2026.

